MMV 1804559 is a potential antistaphylococcal and antibiofilm agent targeting the clfA gene of Staphylococcus aureus.

Autor:	Brahma U; National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad., Singothu S; National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad., Suresh A; National Institute of Animal Biotechnology.; Manipal Academy of Higher Education, Manipal 576104, India., Vemula D; National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad., Munglashetty S; National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad., Sharma P; National Institute of Animal Biotechnology., Bhandari V; National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad.
Jazyk:	angličtina
Zdroj:	Journal of applied microbiology [J Appl Microbiol] 2024 Oct 29. Date of Electronic Publication: 2024 Oct 29.
DOI:	10.1093/jambio/lxae276
Abstrakt:	Aim: Staphylococcus aureus, a high-priority pathogen proclaimed to cause infections ranging from mild to life-threatening, presents significant challenges in treatment. New therapies can be developed quicker using open drug discovery platforms offering a distinct approach to expedite the development of innovative antibacterial and anti-biofilm therapeutics. This study set out to address these issues by finding new uses for current medications to find compounds that are effective against S. aureus. Methods and Results: In this study, we screened the global priority health box, launched by Medicines for Malaria Ventures containing 240 compounds, for their effectiveness against S. aureus. MMV1795508, MMV1542799, MMV027331, MMV1593278, and MMV1804559 showed potential antibacterial activity at 10 µM concentration. These compounds underwent further evaluation for their ability to clear intracellular bacteria, disrupt biofilm formation and eradicate existing biofilms. MMV1804559 demonstrated strong efficacy across all tested parameters, achieving 94% inhibition of intracellular bacteria, 79.19% disruption of biofilm cells, and 66.18% inhibition of biofilm formation. Scanning electron microscopy revealed notable membrane perforations and blebbing in MMV1804559-treated cells, indicating its impact on bacterial membranes. Gene expression analysis of cells treated with MMV1804559 showed downregulation of clfA and clfB genes, critical for biofilm formation. Additionally, docking studies confirmed the binding affinity of MMV1804559 with clfA, supported by favorable docking scores, MM/GBSA binding energy, and increased hydrogen bond interactions in the binding pocket, suggesting clfA as a target for MMV1804559. Conclusion: MMV1804559 could serve as a potential therapy for S. aureus by targeting biofilm development and cell adhesion processes. (© The Author(s) 2024. Published by Oxford University Press on behalf of Applied Microbiology International.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu